Not Yet Recruiting
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma
NCT07309419
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
- Locations
-
Not specified